Metabolic dysfunctions are one of the major contributors to the development of Alzheimer’s Disease (AD). They are one of the main causes of the inflammatory ...
Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug discovery ...
They grew their organoids in a lab using human induced pluripotent stem cells from healthy donors and patients with MS and Parkinson's disease. These are stem cells that are created by taking normal ...